Pharmaceutical industry
Magen BioSciences, Inc., a biotechnology company developing agents to promote human skin health, has secured a significant investment from notable venture capital firms. The company has attracted $1.8 million from ARCH Venture Partners, TVM Capital, and Venrock Associates, with participation from Alexandria Real Estate and Lux Capital. This funding
Pharmaceutical industry
As reported by Genetic Engineering News (www.genengnews.com), Amgen (AMGN:NASDAQ) has topped the list of the "Top 50 Biotech Companies" with a market capitalization of $93.09 billion as of this year. This impressive number is a testament to the company's success in transitioning
Pharmaceutical industry
Best Practices, LLC has introduced a comprehensive Best Practice and Benchmarking Database aimed at providing biotech executives and managers with strategic market data to assist in planning and managing new product introductions. The database offers a flat fee for access to valuable content, including documents that focus on copromotion partnerships,
Pharmaceutical industry
The biotechnology industry in France has experienced significant growth since 1997, with a surge in the emergence of new companies, many of which were created after 1990. Today, France is home to over 400 biotech companies and 600 service providers, boasting a thriving industry that is recognized globally. The 6th
Pharmaceutical industry
Dr. Douglas Powell, director of immunobiology at Antigen Express, presented at the international Bird Flu Summit in Washington, DC, in February, showcasing the company's novel synthetic peptide vaccine designed to combat the avian influenza virus. The vaccine's strategy employs small protein fragments from the H5 protein,
Pharmaceutical industry
Amgen, the world's largest biotechnology company, has announced that the U.S. Food and Drug Administration (FDA) has approved every-three-week dosing of Aranesp(R) (darbepoetin alfa) for the treatment of chemotherapy-induced anemia in patients with non-myeloid malignancies. Aranesp is the only erythropoiesis-stimulating agent approved by the FDA for
Pharmaceutical industry
A US Food and Drug Administration (FDA) advisory panel is set to discuss the potential re-approval of the multiple sclerosis drug Tysabri, also known as natalizumab, which has been linked to a rare brain disease and other infections. The panel will examine the risks and benefits of the drug, which
Pharmaceutical industry
Catalyst Biosciences, Inc., a privately held biotechnology company focused on engineering and developing therapeutic protease products, has raised $30 million in its series B financing. The investment was led by Morgenthaler Ventures, with participation from HealthCare Ventures and all of Catalyst's previous investors, including Sofinnova Ventures, Burrill &
Pharmaceutical industry
DNAPrint Genomics, Inc. has entered into a research sponsorship agreement with the Massachusetts College of Pharmacy and Health Sciences to develop Ritalin-like compounds as potential medications for drug addiction, ADHD, and depression. The partnership aims to create "theranostic" test/drug combinations that use genomics to ensure patients receive
Pharmaceutical industry
As the world of biotechnology and pharmaceuticals continues to evolve, several medical and health stocks have caught the attention of investors and market analysts. StockstoFollow.com, a leading online financial portal, identifies key companies that are poised to advance in the market due to their innovative technology, executive teams, and
Pharmaceutical industry
Tanox, Inc., a biotechnology company specializing in the discovery and development of monoclonal antibodies, has received a significant $12.8 million net milestone payment from Genentech, Inc., based on the achievement of $300 million in 2005 U.S. sales of Xolair (omalizumab). This payment was made under the terms of
Pharmaceutical industry
Callisto Pharmaceuticals, a developer of new cancer therapies, has exclusive rights to a groundbreaking new drug called Degrasyn, designed to target a wide range of cancer tumors. This significant acquisition expands Callisto's pipeline, doubling its focus on solid tumor cancers and positioning the company for future success. With
